Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elranatamab - Pfizer

Next Previous
Drug Profile

Elranatamab - Pfizer

Alternative Names: Elranatamab-bcmm; ELREXFIO; Elrexfio; PF-06863135; PF‑3135; RN-613

Latest Information Update: 31 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer ALX Oncology; Pfizer
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma

Most Recent Events

  • 27 Oct 2026 Efficacy and adverse events data from a phase III MagnetisMM-32 trial in Multiple myeloma released by Pfizer
  • 11 Jun 2026 Updated efficacy and adverse event data from the phase Ib MagnetisMM-20 trial in Multiple myeloma presented at the 31st Congress of the European Haematology Association (EHA-2026)
  • 02 Jun 2026 Efficacy and adverse event data from phase II ERASMM trial for Multiple myeloma presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top